Intravitreal Injection of Brolucizumab for Recalcitrant Macular Edema due to Central Retinal Vein Occlusion: A Small Case Series

Chakraborty, D. P.; Mondal, Soumen; Boral, Subhendu; Das, Asim K.

doi:10.1159/000526710

Cited by 4 publications

(5 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mean CMT @ presentation was 577.29 microns & 615.5 microns while the mean reduction was 290.15 microns & 360 microns in BRVO & CRVO respectively. Previous case report [20] showed recurrence of edema @ 16 weeks, while in our case series only 1 patient had recurrence of edema @ 12 weeks in CRVO category, while 9 patients (7 in CRVO, 2 in BRVO ) had sub-optimal reduction in edema warranting repeat dose of brolucizumab.…”

Section: Discussioncontrasting

confidence: 59%

“…More gain in vision in CRVO may be attributed to more initial drop in vision in these cases. Previous case reports also showed the visual gain which were maintained for a period of 2-3 months [20,21] . Mean CMT @ presentation was 577.29 microns & 615.5 microns while the mean reduction was 290.15 microns & 360 microns in BRVO & CRVO respectively.…”

Section: Discussionmentioning

confidence: 67%

“…Brolucizumab (Br) has shown non-inferiority to a ibercept in clinical trials related to neovascular age related macular degeneration (nAMD) [18] & diabetic macular oedema [19] with 12 weekly injection dosage. 2 short term case reports [20,21] on 3 eyes of recalcitrant macular oedema in RVO cases demonstrated visual acuity gain with reduction of uid which lasted upto 8-12 weeks.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Real world experience of Brolucizumab in recurrent macular oedema in Retinal Vein Occlusions : 12 months follow up

Narnaware,

Bawankule,

Raje

et al. 2023

Preprint

View full text Add to dashboard Cite

Purpose : To evaluate real world outcome in recurrent macular oedema secondary to retinal vein occlusion in relation to anatomical success , visual outcomes and safety of intravitreal brolucizumab injection at 1 year. Methods : Prospective, randomized study between July 2022 to June 2023 on 17 eyes of 32 patients. Patients were divided into Group 1 : BRVO with ME , Group 2 : CRVO with ME. BCVA, CMT, and number of injections at 1 year were evaluated. From beginning patients were treated on PRN basis. Results: Study included 17 eyes with a mean age of 63.65 (SD: 10.68) years, and among these, 7 (41.2% ) were diagnosed with BRVO and 10 (58.8%) with CRVO. There was statistically significant improvement BCVA at 12 months in both the categories (P < 0.0001). Mean CMT also reduced significantly in both categories at 12 months (P < 0.0001). Median number of injections required was 2.0, while mean interval between two injections was 4.06 (SD: 1.91) months. Conclusion: In real-world scenario, with 1 year follow up , brolucizumab is found to be efficacious and safe with less need injections and more interval free period in management of recurrent ME due to RVO’s

show abstract

Section: Discussioncontrasting

confidence: 59%

Section: Discussionmentioning

confidence: 67%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Real world experience of Brolucizumab in recurrent macular oedema in Retinal Vein Occlusions : 12 months follow up

Narnaware,

Bawankule,

Raje

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…One clear example is seen in the impact of COVID‐19 on the more aggressive discharge patterns. It can be further speculated that introduction of new anti‐VEGF formulations or treatment may also influence treatment burden (Chakraborty et al, 2022; Dugel et al, 2020; Ghanchi et al, 2022; Heier et al, 2022). However, for RVO, studies on Aflibercept and Ranibizumab have so far not shown any clear differences in the number of injections beyond the first year (Corazza et al, 2022).…”

Section: Discussionmentioning

confidence: 99%

Prognostic modelling of number of patients with retinal vein occlusion in anti‐VEGF therapy

Subhi

Potapenko

Hajari

et al. 2023

Acta Ophthalmologica

View full text Add to dashboard Cite

PurposeThe purpose of the study was to evaluate temporal changes in age‐ and sex‐stratified incidence rates of retinal vein occlusion (RVO) commenced in anti‐vascular endothelial growth factor (anti‐VEGF) treatment, proportion of patients remaining in active anti‐VEGF therapy over time, and to develop a forecasting model for future number of patients with RVO in active anti‐VEGF therapy.MethodsThis was a registry‐based study of patients with RVO in the Capital Region of Denmark from commenced in anti‐VEGF therapy from 1 January 2007 to 30 June 2022. Census data were extracted from Statistics Denmark for incidence rate analyses and forecasting data of future demographics.ResultsA total of 2641 patients with RVO were commenced in anti‐VEGF therapy, of which 2192 were later discontinued. Number of patients rose dramatically during the first years of introduction of anti‐VEGF therapy, after which growth was slower and followed the demographic changes. Trend analyses revealed that the COVID‐19 epidemics impacted with fewer referrals and more aggressive discontinuation practices. Annual incidence of RVO in 2012–2021 was 13.1 per 100 000 (95% CI: 12.6–13.6 per 100 000). Proportion of patients with RVO remaining in active anti‐VEGF treatment was 55.0%, 40.1%, 30.8% and 12.1% after Years 1, 2, 3 and 8, respectively. According to our forecast, number of patients with RVO in active anti‐VEGF therapy will grow slowly but continually at least until year 2035.ConclusionOur study reports incidence rates and provides prognostic modelling of number of patients with RVO in anti‐VEGF therapy.

show abstract

“…Some economic studies show better costeffectiveness for Ranibizumab compared with A ibercept(52); however, network meta-analysis showed slightly better visual outcomes for A ibercept compared with Ranibizumab(53), while others show no difference between available anti-VEGF in e cacy (54)(55)(56) or in IOP (57). Recently anti-VEGF available like Faricimab are being evaluated in RVO (BALATON and COMINO clinical trials)(58), or Bevacizumab in some available case reports (59).…”

Section: Guideline Clinical Recommendation Meta-synthesismentioning

confidence: 99%

Systematic review of clinical practice guidelines for the diagnosis and management of retinal vein occlusion

Galvez-Olortegui,

Bouchikh-El Jarroudi,

Silva-Ocas

et al. 2024

Eye

View full text Add to dashboard Cite

Background/Objectives:To assess the Clinical Practice Guidelines (CPG) for the diagnosis and management of Retinal Vein Occlusion (RVO). Methods:A systematic review of CPGs for the diagnosis and management of RVO, published between January-2010 and April-2022, was carried out with a search in databases, metasearch engines, CPG development institutions, ophthalmology associations and CPG repositories.CPGs in English/Spanish were selected, and 5 authors evaluated them independently, using the Appraisal of Guidelines for Research and Evaluation(AGREE-II) instrument. An individual assessment of each CPG by domain(AGREE-II), an overall assessment of the guide, and its use with or without modi cations was performed. Additionally, a meta-synthesis of the recommendations for the most relevant outcomes was carried out. Results:5/6 CPGs scored low in domain 3(rigour of development), and the highest score(mean 62%) was for domain 4(clarity of presentation). 2019 American guideline (PPP) presented the best score(40.4%) in domain 3. When evaluating the overall quality of the CPGs analyzed, all CPGs could be recommended with modi cations. In the meta-synthesis, anti-VEGF therapy is the rst-choice therapy for macular edema associated with RVO, but there is no clear recommendation about the type of anti-VEGF therapy to choose. Recommendations for diagnosis and follow-up are similar among CPGs evaluated. Conclusion:Most CPGs for the diagnosis and management of retinal vein occlusion have a low methodological quality evaluated according to the AGREE-II. PPP has the higher score in the domain "Rigour of Development". Among the CPGs evaluated, there is no clear recommendation on the type of anti-VEGF therapy to choose.

show abstract

Intravitreal Injection of Brolucizumab for Recalcitrant Macular Edema due to Central Retinal Vein Occlusion: A Small Case Series

Cited by 4 publications

References 22 publications

Real world experience of Brolucizumab in recurrent macular oedema in Retinal Vein Occlusions : 12 months follow up

Real world experience of Brolucizumab in recurrent macular oedema in Retinal Vein Occlusions : 12 months follow up

Prognostic modelling of number of patients with retinal vein occlusion in anti‐VEGF therapy

Systematic review of clinical practice guidelines for the diagnosis and management of retinal vein occlusion

Contact Info

Product

Resources

About